Licensing – Talk Bio

Actionable Insights Powered by AI

Alphabet’s Calico Strikes $596M Deal for Mabwell’s Anti-Aging Antibody

4 weeks ago talkbio0Tagged aging-related diseases, Alphabet, Antibodies, Biopharma, Calico, interleukin-11, Licensing, Mabwell

Calico; Alphabet; Mabwell; anti-aging; biotech; IL-11 antibody; 9MW3811; exclusive licensing; aging-related diseases; biopharma deal

InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech

6 months ago talkbio0Tagged Antibodies, Bispecific, InnoCare, Investments, KeyMed, Licensing, RTW

InnoCare, KeyMed, Bispecific Antibody, RTW Investments, Licensing Deal, $520M

Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration

1 year ago talkbio0Tagged Adaptimmune, biobucks, Collaboration, financing characteristics, Galapagos, Licensing, Melanoma-Associated Antigen 4, next-generation therapy, T-Cell Receptor, T-cell therapy

Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy

Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring

1 year ago talkbio0Tagged cancer drugs, China, Erasca, Licensing, strategic shift

Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift